Andreanne Loiselle
Quebec, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: October 01, 2025
Distinct alterations of adiponectin, fibroblast growth factor 21 (FGF-21), and insulin-like growth factor binding protein 2 (IGFBP-2) link dysmetabolism with cognitive decline across the Alzheimer's disease spectrum.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: September 16, 2025
Beneficial effects of miR-132/212 deficiency in the zQ175 mouse model of Huntington's disease.
Journal: Frontiers in neuroscience
Published: April 22, 2024
Correction to: Higher angiotensin‑converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.
Journal: Acta neuropathologica communications
Published: November 02, 2023
Higher angiotensin-converting enzyme 2 (ACE2) levels in the brain of individuals with Alzheimer's disease.
Journal: Acta neuropathologica communications
Published: August 29, 2023
Widespread alterations in microRNA biogenesis in human Huntington's disease putamen.
Journal: Acta neuropathologica communications
Published: May 24, 2022
Marker-free co-selection for successive rounds of prime editing in human cells.
Journal: Nature communications
Published: December 03, 2021
MicroRNA-138 Overexpression Alters Aβ42 Levels and Behavior in Wildtype Mice.
Journal: Frontiers in neuroscience
Published: August 03, 2020
Advances and Challenges in Understanding MicroRNA Function in Tauopathies: A Case Study of miR-132/212.
Journal: Frontiers in neurology
Published: July 01, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026